TheTechno Optimist.

StoryTest

Boehringer Ingelheim reports phase 3 SYNCHRONIZE-1 positive results: 16.6% weight loss with Survodutide in obesity

Boehringer Ingelheim / Zealand PharmaSurvodutide (BI 456906)

Boehringer Ingelheim announced positive SYNCHRONIZE-1 phase 3 results for Survodutide in obesity. Patients achieved 16.6% mean weight loss after 76 weeks. A pre-specified substudy showed 34% visceral fat and 63% liver fat reduction, directly addressing MASH.

  • 16.6% mean weight loss (39.2 lb / 17.8 kg) after 76 weeks.
  • 34% visceral fat reduction; 63% liver fat reduction in MASH substudy.
  • Minimal lean muscle mass loss versus GLP-1-only drugs.
  • Licensed from Zealand Pharma; Boehringer Ingelheim handles global development.
Read the original · Press Biotech

More on Survodutide (BI 456906)

Primer